X4 Pharmaceuticals, Inc·4

Nov 2, 4:58 PM ET

Ragan Paula 4

4 · X4 Pharmaceuticals, Inc · Filed Nov 2, 2023

Insider Transaction Report

Form 4
Period: 2023-10-31
Ragan Paula
DirectorPresident and CEO
Transactions
  • Award

    Common Stock

    2023-10-31+532,0811,075,878 total
Footnotes (1)
  • [F1]Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.

Documents

1 file
  • 4
    wk-form4_1698958692.xmlPrimary

    FORM 4